Orchestra BioMed Hldgs Analyst Ratings
Chardan Capital Reiterates Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
Orchestra BioMed Hldgs Analyst Ratings
Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
Piper Sandler Sticks to Its Buy Rating for Orchestra BioMed Holdings (OBIO)
Buy Rating Affirmed for Orchestra BioMed on Strong Financials and Promising BackBeat CNT Clinical Data
Jefferies Initiates Coverage On Orchestra BioMed Hldgs With Buy Rating, Announces Price Target of $14
Orchestra BioMed Hldgs Analyst Ratings
Buy Rating for Orchestra BioMed Holdings: An Optimistic Outlook on BACKBEAT and Virtue SAB Studies' Potential Impact and Future Developments
Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO) and Bicycle Therapeutics (BCYC)
Analysts Offer Insights on Healthcare Companies: Reneo Pharmaceuticals (RPHM), Pulmonx (LUNG) and Orchestra BioMed Holdings (OBIO)
Orchestra BioMed Holdings (OBIO) Gets a Buy From LifeSci Capital
LifeSci Capital Sticks to Their Buy Rating for Orchestra BioMed Holdings (OBIO)
Chardan Capital Reiterates Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
Orchestra BioMed Hldgs Analyst Ratings
Orchestra BioMed Hldgs Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO), Anavex Life Sciences (AVXL) and Recursion Pharmaceuticals (RXRX)
Orchestra BioMed Holdings (OBIO) Gets a Buy From Chardan Capital
LifeSci Capital Reaffirms Their Buy Rating on Orchestra BioMed Holdings (OBIO)
Chardan Capital Reiterates Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
No Data